Table 5:

Findings at last follow-up.

Findings at last follow up	N=39
Mean post-transplant follow up (years)	27.4 ± 1.9
Pancreas graft outcomes
Functional graft, not requiring medications	35 (89.7%)
On low-dose insulin or oral agent to control blood sugar	4 (10.3%)
Functionality
Independent	35 (89.7%)
Dependent for activities of daily living	4 (10.3%)
Hypertension	38 (97.4%)
Hyperlipidemia	26 (66.7%)
Coronary artery disease	11 (28.2%)
DSA findings on last follow up
Never tested	6 (15.4%)
Negative on last check:	20 (51.3%)
Positive on last check:	13 (33.3%)
Current immunosuppressive medications:
Three drug regimen	24 (61.5%)
Aza + CNI + steroids	8 (33.3%)
MPA + CNI + steroids	14 (58.3%)
Aza + sirolimus + steroids	2 (8.3%)
Two drug regimen	13 (33.3%)
MPA + steroids	4 (30.8%)
CNI + steroids	8 (61.5%)
Aza + steroids	1 (7.7%)
One drug regimen	2 (5.2%)
Steroids	2 (100.0%)
Mean HgbA1c (%)	5.6 ± 0.6
Mean serum creatinine mg/dl (n=28)	1.6 ± 0.6
Mean eGFR (ml/min/1.73m2)	45.9 ± 20.3
Average weight gain post-transplant (kg)	10.9 ± 16.9

Abbreviations: DSA, donor-specific antibody; Aza, azathioprine; CNI, calcineurin-inhibitor; MPA, mycophenolic acid